Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy

The receptor tyrosine kinase VEGFR-3 plays a crucial role in cancer-induced angiogenesis and lymphangiogenesis, promoting tumor development and metastasis. Here, we report the novel VEGFR-3 inhibitor EVT801 that presents a more selective and less toxic profile than two major inhibitors of VEGFRs (i....

Descripción completa

Detalles Bibliográficos
Autores principales: Paillasse, Michael R., Esquerré, Michael, Bertrand, Florie A., Poussereau-Pomié, Céline, Pichery, Mélanie, Visentin, Virgile, Gueguen-Dorbes, Geneviève, Gaujarengues, Florence, Barron, Pauline, Badet, Gaelle, Briaux, Anne, Ancey, Pierre-Benoit, Sibrac, David, Erdociain, Eric, Özcelik, Dennis, Meneyrol, Jérôme, Martin, Valérie, Gomez-Brouchet, Anne, Selves, Janik, Rochaix, Philippe, Battistella, Maxime, Lebbé, Céleste, Delord, Jean-Pierre, Dol-Gleizes, Frédérique, Bono, Françoise, Blanc, Isabelle, Alam, Antoine, Hunneyball, Ian, Whittaker, Mark, Fons, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035370/
https://www.ncbi.nlm.nih.gov/pubmed/36970050
http://dx.doi.org/10.1158/2767-9764.CRC-22-0151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035370/
https://www.ncbi.nlm.nih.gov/pubmed/36970050
http://dx.doi.org/10.1158/2767-9764.CRC-22-0151

Ejemplares similares